NextPharma operates ten pharmaceutical manufacturing and development sites across Europe, each structured as a centre of excellence for a defined set of dosage forms, technologies or containment requirements. If you are evaluating a CDMO for development, clinical supply or commercial manufacturing, or looking for a specific capability within an existing partnership, this page maps our entire network and links directly to each site.
The network is organised so that each product type is handled in the most appropriate environment. Our sites are not interchangeable: each carries defined technical ownership, its own regulatory authorisations, and a manufacturing scope aligned to its specialisation.
Large-scale manufacturing for chewable tablets and high-volume solid dosage forms
Liquid-filled hard capsules, including high-containment and controlled substance handling; UK MHRA-authorised site
Oral solids manufacturing and EU clinical trials supply hub, including GMP batch manufacture, packaging, labelling, and distribution
Oral liquids, suppositories and non-sterile double-point ampoules; French MA support
Centre of excellence for softgels and lipid-based formulations, pharma-ceutical and nutritional applications; Xcelodose microdosing available
Centre of excellence for sterile ophthalmics and otics, including BFS, multi-dose and preservative-free multi-dose formulations
High-containment manufacturing for hormones (oral solids, semi-solids, liquids) alongside conventional semi-solid and liquid dosage forms
Projects within the network are assigned to the appropriate site based on dosage form, containment requirements and regulatory constraints, not on availability alone. This model ensures continuity across development, clinical and commercial stages, retains technical knowledge within the same organisation and provides clear accountability for each manufacturing activity.
For a full picture of how services are structured across the network, explore commercial manufacturing and packaging or clinical trials services at NextPharma.
All ten sites operate under GMP conditions, with quality systems aligned at network level to ICH Q9 (quality risk management) and ICH Q10 (pharmaceutical quality systems). Each site holds its own regulatory authorisations depending on its manufacturing scope. The network is inspected by major authorities including:
Site-specific GMP certificates, inspection history and regulatory scope are available on each location’s dedicated page.
Talk to our business development team about your programme requirements and contact us to get started.
Whether it's development, manufacturing or supply. Tell us about your project and our experts will get back to you.
